Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 9.61% | $254.01M | £210.77B | 35.66% | 76 Outperform | |
| HSBC Holdings | 8.36% | $220.95M | £179.93B | 43.68% | 79 Outperform | |
| Shell (UK) | 7.53% | $198.96M | £160.28B | 8.34% | 77 Outperform | |
| Unilever | 5.01% | $132.33M | £109.80B | -1.32% | 77 Outperform | |
| Rolls-Royce Holdings | 4.12% | $109.03M | £89.61B | 104.42% | 71 Outperform | |
| British American Tobacco | 3.97% | $104.94M | £90.78B | 43.11% | 60 Neutral | |
| BP p.l.c. | 3.31% | $87.42M | £69.84B | 17.92% | 63 Neutral | |
| GlaxoSmithKline | 3.30% | $87.14M | £71.60B | 34.44% | 82 Outperform | |
| Rio Tinto | 2.73% | $72.21M | £90.22B | 8.38% | 79 Outperform | |
| Barclays | 2.59% | $68.42M | £55.57B | 51.44% | 76 Outperform |